The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Ascorbic acid enhances arsenic trioxide–induced cytotoxicity in multiple myeloma cells
Open accessAbstract
Multiple myeloma (MM) is a clonal B-cell malignancy characterized by slow-growing plasma cells in the bone marrow (BM). Patients with MM typically respond to initial chemotherapies; however, essentially all progress to a chemoresistant state. Factors that contribute to the chemorefractory phenotype include modulation of free radical scavenging, increased expression of drug efflux pumps, and changes in gene expression that allow escape from apoptotic signaling. Recent data indicate that arsenic trioxide (As2O3) induces remission of refractory acute promyelocytic leukemia and apoptosis of cell lines overexpressing Bcl-2 family members; therefore, it was hypothesized that chemorefractory MM cells would be sensitive to As2O3. As2O3 induced apoptosis in 4 human MM cell lines: 8226/S, 8226/Dox40, U266, and U266/Bcl-xL. The addition of interleukin-6 had no effect on cell death. Glutathione (GSH) has been implicated as an inhibitor of As2O3-induced cell death either through conjugating As2O3 or by sequestering reactive oxygen induced by As2O3. Consistent with this possibility, increasing GSH levels with N-acetylcysteine attenuated As2O3 cytotoxicity. Decreases in GSH have been associated with ascorbic acid (AA) metabolism. Clinically relevant doses of AA decreased GSH levels and potentiated As2O3-mediated cell death of all 4 MM cell lines. Similar results were obtained in freshly isolated human MM cells. In contrast, normal BM cells displayed little sensitivity to As2O3 alone or in combination with AA. Together, these data suggest that As2O3 and AA may be effective antineoplastic agents in refractory MM and that AA might be a useful adjuvant in GSH-sensitive therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Self-citationAutocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633
Shen, Z.-X., Chen, G.-Q., Ni, J.-H., Li, X.-S., Xiong, S.-M., Qiu, Q.-Y., Zhu, J., Tang, W., Sun, G.-L., Yang, K.-Q., et al. (1997) · Blood · doi:10.1182/blood.v89.9.3354 · Cited by 1,428
Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide
Soignet, S. L., Maslak, P., Wang, Z.-G., Jhanwar, S., Calleja, E., Dardashti, L. J., Corso, D., DeBlasio, A., Gabrilove, J., Scheinberg, D. A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391901 · Cited by 1,213
Dysregulation of Apoptosis in Cancer
Reed, J. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2941 · Cited by 987
Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A., & Dalton, W. S. (1999) · Blood · doi:10.1182/blood.v93.5.1658 · Cited by 901
Self-citationChen, G., Zhu, J., Shi, X., Ni, J., Zhong, H., Si, G., Jin, X., Tang, W., Li, X., Xong, S., et al. (1996) · Blood · doi:10.1182/blood.v88.3.1052.1052 · Cited by 864
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process
Hallek, M., Leif Bergsagel, P., & Anderson, K. C. (1998) · Blood · doi:10.1182/blood.v91.1.3 · Cited by 752
Criteria and recommendations for vitamin C intake
Levine, M. (1999) · JAMA · doi:10.1001/jama.281.15.1415 · Cited by 559
Dalton, W. S., Grogan, T. M., Meltzer, P. S., Scheper, R. J., Durie, B. G., Taylor, C. W., Miller, T. P., & Salmon, S. E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.415 · Cited by 556
Self-citationDai, J., Weinberg, R. S., Waxman, S., & Jing, Y. (1999) · Blood · doi:10.1182/blood.v93.1.268 · Cited by 540
Interleukin-6 in human multiple myeloma
Klein, B., Zhang, X., Lu, Z., & Bataille, R. (1995) · Blood · doi:10.1182/blood.v85.4.863.bloodjournal854863 · Cited by 520
Mammalian facilitative hexose transporters mediate the transport of dehydroascorbic acid
Vera, J. C., Rivas, C. I., Fischbarg, J., & Golde, D. W. (1993) · Nature · doi:10.1038/364079a0 · Cited by 496
Reactions of arsenic(III) and arsenic(V) species with glutathione
Scott, N., Hatlelid, K. M., MacKenzie, N. E., & Carter, D. E. (1993) · Chemical Research in Toxicology · doi:10.1021/tx00031a016 · Cited by 458
Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy
Jennings, C. D., & Foon, K. A. (1997) · Blood · doi:10.1182/blood.v90.8.2863 · Cited by 447
Kala, S. V., Neely, M. W., Kala, G., Prater, C. I., Atwood, D. W., Rice, J. S., & Lieberman, M. W. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m007030200 · Cited by 317
Chauhan, D., Kharbanda, S., Ogata, A., Urashima, M., Teoh, G., Robertson, M., Kufe, D. W., & Anderson, K. C. (1997) · Blood · doi:10.1182/blood.v89.1.227 · Cited by 272
Zhu, X.-H., Shen, Y.-L., Jing, Y.-K., Cai, X., Jia, P.-M., Huang, Y., Tang, W., Shi, G.-Y., Sun, Y.-P., Dai, J., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.9.772 · Cited by 272
Flens, M. J., Izquierdo, M. A., Scheffer, G. L., Fritz, J. M., Meijer, C. J. L. M., Scheper, R. J., & Zaman, G. J. (1994) · PubMed · Cited by 272
Interleukin-6 Inhibits Apoptosis of Malignant Plasma Cells
Lichtenstein, A., Tu, Y., Fady, C., Vescio, R., & Berenson, J. (1995) · Cellular Immunology · doi:10.1006/cimm.1995.1076 · Cited by 271
Allogeneic transfusion and infection: economic and clinical implications.
Sonneveld, P., Lokhorst, H. M., & Vossebeld, P. J. M. (1997) · PubMed · Cited by 267
Interleukin-6 prevents dexamethasone-induced myeloma cell death
Hardin, J., MacLeod, S., Grigorieva, I., Chang, R., Barlogie, B., Xiao, H., & Epstein, J. (1994) · Blood · doi:10.1182/blood.v84.9.3063.3063 · Cited by 262
Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein.
Dalton, W. S., Durie, B. G. M., Alberts, D. S., Gerlach, J. H., & Cress, A. E. (1986) · PubMed · Cited by 259
Self-citationPerkins, C., Kim, C. N., Fang, G., & Bhalla, K. N. (2000) · Blood · doi:10.1182/blood.v95.3.1014.003k04_1014_1022 · Cited by 232
BCL-X expression in multiple myeloma: possible indicator of chemoresistance.
Tu, Y., Renner, S., Xu, F., Fleishman, A. N., Taylor, J. M. G., Weisz, J., Vescio, R. A., Rettig, M. B., Berenson, J., Krajewski, S., et al. (1998) · PubMed · Cited by 222
Broeks, A., Gerrard, B., Allikmets, R., Dean, M., & Plasterk, R. H. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01001.x · Cited by 219
Ludwig, S., Hoffmeyer, A., Goebeler, M., Kilian, K., Häfner, H., Neufeld, B., Han, J., & Rapp, U. R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.4.1917 · Cited by 210
Loe, D. W., Stewart, R. K., Massey, T. E., Deeley, R. G., & Cole, S. P. C. (1997) · Molecular Pharmacology · doi:10.1124/mol.51.6.1034 · Cited by 195
Detection of the M(r) 190,000 multidrug resistance protein, MRP, with monoclonal antibodies.
Hipfner, D. R., Gauldie, S. D., Deeley, R. G., & Cole, S. P. C. (1994) · PubMed · Cited by 195
Akao, Y., Nakagawa, Y., & Akiyama, K. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00841-8 · Cited by 184
Welch, R. W., Wang, Y., Crossman, A., Park, J. B., Kirk, K. L., & Levine, M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.21.12584 · Cited by 181
Clinical multidrug resistance in cancer: A multifactorial problem
Lehnert, M. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00069-x · Cited by 176
Phase I Study of Continuous-Infusion L-S,R-Buthionine Sulfoximine With Intravenous Melphalan
Bailey, H. H., Ripple, G., Tutsch, K. D., Arzoomanian, R. Z., Alberti, D., Feierabend, C., Mahvi, D., Schink, J., Pomplun, M., Mulcahy, R. T., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.23.1789 · Cited by 164
The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms
Zhang, W., Ohnishi, K., Shigeno, K., Fujisawa, S., Naito, K., Nakamura, S., Takeshita, K., Takeshita, A., & Ohno, R. (1998) · Leukemia · doi:10.1038/sj.leu.2401112 · Cited by 158
Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid.
O'Dwyer, P. J., LaCreta, F. P., Nash, S., Tinsley, P. W., Schilder, R. J., Clapper, M. L., Tew, K. D., Panting, L., Litwin, S., & Comis, R. L. (1991) · PubMed · Cited by 145
Pharmacological considerations in the modulation of multidrug resistance
Fisher, G. A., Lum, B. L., Hausdorff, J., & Sikic, B. I. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00111-6 · Cited by 133
Akao, Y., Mizoguchi, H., Kojima, S., Naoe, T., Ohishi, N., & Yagi, K. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00869.x · Cited by 127
Lee, T. C., Wei, M. L., Chang, W. J., Ho, I., Lo, J. F., Jan, K. Y., & Huang, H. (1989) · In Vitro Cellular & Developmental Biology - Plant · doi:10.1007/bf02624629 · Cited by 125
Development and characterization of a melphalan-resistant human multiple myeloma cell line.
Bellamy, W. T., Dalton, W. S., Gleason-Guzman, M. C., Grogan, T. M., & Trent, J. M. (1991) · PubMed · Cited by 125
Self-citationXu, F., Sharma, S., Gardner, A. M., Tu, Y., Raitano, A. B., Sawyers, C. L., & Lichtenstein, A. K. (1998) · Blood · doi:10.1182/blood.v92.1.241.413k28_241_251 · Cited by 113
Moalli, P., Pillay, S., Weiner, D., Goldman-Leikin, R. E., & Rosen, S. (1992) · Blood · doi:10.1182/blood.v79.1.213.bloodjournal791213 · Cited by 112
Hipfner, D. R., Almquist, K. C., Stride, B. D., Deeley, R. G., & Cole, S. P. C. (1996) · PubMed · Cited by 106
Xu, F., Gardner, A. M., Tu, Y., Michl, P., Prager, D., & Lichtenstein, A. K. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.592708.x · Cited by 101
Ochi, T., Kaise, T., & Oya-Ohta, Y. (1994) · Cellular and Molecular Life Sciences · doi:10.1007/bf01984946 · Cited by 83
Modulating factors of radical intensity and cytotoxic activity of ascorbate (review).
Sakagami, H., & Satoh, K. (1997) · PubMed · Cited by 80
Gomi, M., Moriwaki, K., Katagiri, S., Kurata, Y., & Thompson, E. B. (1990) · PubMed · Cited by 72
Mechanisms involved in sodium arsenite-induced apoptosis of human neutrophils
William, R., Watson, G. W., Redmond, H. P., Wang, J. H., & Bouchier-Hayes, D. (1996) · Journal of Leukocyte Biology · doi:10.1002/jlb.60.5.625 · Cited by 69
Differential cytotoxicity of sodium arsenite in human fibroblasts and Chinese hamster ovary cells
Lee, T., Ko, J., & Jan, K. Y. (1989) · Toxicology · doi:10.1016/0300-483x(89)90092-9 · Cited by 60
Antimutagenic and promutagenic activity of ascorbic acid during oxidative stress
Bijur, G. N., Ariza, M. E., Hitchcock, C. L., & Williams, M. V. (1997) · Environmental and Molecular Mutagenesis · doi:10.1002/(sici)1098-2280(1997)30:3<339::aid-em13>3.0.co;2-e · Cited by 57
Glutathione S-transferase π in an arsenic-resistant Chinese hamster ovary cell line
Lo, J. F., Wang, H. F., Tam, M. F., & Lee, T. (1992) · Biochemical Journal · doi:10.1042/bj2880977 · Cited by 54
Reversing of chlorambucil resistance by ethacrynic acid in a B‐CLL patient
Petrini, M., Conte, A., Caracciolo, F., Sabbatini, A. R. M., Grassi, B., & Ronca, G. (1993) · British Journal of Haematology · doi:10.1111/j.1365-2141.1993.tb03187.x · Cited by 35
Block, G., Henson, D. E., & Levine, M. N. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-10-909 · Cited by 30
Thalidomide in Multiple Myeloma
Kishi, Y., Oki, Y., & Machida, U. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003303421313 · Cited by 27
Recent Advances in Biology and Treatment of Multiple Myeloma
Abe, M. (2015) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.104.305 · Cited by 4
Cited by
ROS stress in cancer cells and therapeutic implications
Pelicano, H., Carney, D., & Huang, P. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.01.004 · Cited by 2,006
Vitamin C pharmacokinetics: Implications for oral and intravenous use
Padayatty, S. J., Sun, H., Wang, Y., Riordan, H. D., Hewitt, S. M., Katz, A., Wesley, R. A., & Levine, M. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-7-200404060-00010 · Cited by 992
Reactive oxygen species and cancer paradox: To promote or to suppress?
Galadari, S., Rahman, A., Pallichankandy, S., & Thayyullathil, F. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.004 · Cited by 893
Anticancer Activity of Metal Complexes: Involvement of Redox Processes
Jungwirth, U., Kowol, C. R., Keppler, B. K., Hartinger, C. G., Berger, W., & Heffeter, P. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3663 · Cited by 554
Environmental toxicity, oxidative stress and apoptosis: Ménage à Trois
Franco, R., Sánchez-Olea, R., Reyes-Reyes, E. M., & Panayiotidis, M. I. (2009) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2008.11.012 · Cited by 541
Metadata
- Authors
- Grad, J. M., Bahlis, N. J., Reis, I., Oshiro, M. M., Dalton, W. S., & Boise, L. H.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2001-08-01
- Volume
- 98
- Issue
- 3
- Pages
- 805-813
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2049457454
- Cited by
- 271
- References
- 54
- FWCI
- 13.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.